Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns
Lilly says that the FDA wants to look closer at efficacy implications of the Phase III donanemab trial design before giving the green light.
Lilly says that the FDA wants to look closer at efficacy implications of the Phase III donanemab trial design before giving the green light.
What's Your Reaction?
